EMBLEM provides a unique infrastructure to obtain valuable data and samples to study Burkitt’s lymphoma epidemiology. Study data will help characterize or investigate:

  1. The association of malaria-resistance genes with endemic Burkitt’s lymphoma.
  2. Host genetic polymorphisms associated with BL using genome-wide association methods.
  3. The role of EBV genetic variants in endemic Burkitt’s lymphoma.
  4. The role of malaria immunology and phenotype of inflammation in Burkitt’s lymphoma.
  5. The complexity of coinfection with different P. falciparum malaria genotypes in Burkitt’s lymphoma.
  6. The interaction between helminthic parasites, HIV, malaria, and EBV in Burkitt’s lymphoma.
  7. The immunohistochemistry and molecular pathology of Burkitt’s lymphoma.
  8. The impact of malaria, helminthic parasites, and HIV on childhood Burkitt’s lymphoma.

The EMBLEM Study Team welcomes collaboration. EMBLEM principal investigators are the custodians for the data and initial points of contact. Material Transfer Agreements (MTA) will be executed between NCI and the local collaborating institutions before samples are transferred out of the country and all national and international laws related to shipping samples and sharing data will be followed. Genome-wide association study (GWAS) genotype data will be deposited with the NIH GWAS repository, either dbGaP or the NCI caBIG site in accordance with NIH data-sharing policy for GWAS. Data on local residence will be grouped, so that no cell contains less than 15 subjects in order to prevent children from being identified. Scientists will be able to request GWAS data via the NCI Data Access Committee (DAC).

Interested collaborators may contact the EMBLEM Study principal investigator:

Sam M. Mbulaiteye, M.D.
National Institutes of Health/NCI/DCEG
Infections and Immunoepidemiology Branch
9609 Medical Center Dr, Rm. 6E118 MSC 9706
Bethesda MD 20892-9704, USA
Tel: +1 (240) 276-7108; Fax: +1 (240) 276-7836